The clinical trial for a herpes vaccine flouted just about every norm in the book: American patients were flown in to the Caribbean island of St. Kitts for experimental injections. Local authorities didn’t give permission. Nor did the Food and Drug Administration. Nor did a safety panel.

That’s why the trial — run by a startup that has since received funding from billionaire investor Peter Thiel — prompted widespread alarm and censure when it was reported last week by Kaiser Health News.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I find STANFORD PROFESSOR Dr. John Ioannidis’ research incredibly inciteful and all Doctors evaluations to be so accurate. From previous CONUS/OCONUS MEDICAL Clinical Research & IT IMS Mgmt. Lead experience, there was then and I see there is a tremendous need today for USA CENTRALIZED, DESIGN & CONTROLLED INFRASTRUCTURES, UNIVERSALLY DEPLOYED, PROVIDE GUIDANCE & ACOUNTABILITY TO THE ENTIRE Clinical Trials and preclinical trials research.
    There is not an amount or billions of $ that would unify the entire process unless it is one single infrastructures. Of course where a review safety board, lead investigator and clinical teams have their review and suggest qualified and approved deviation.
    With technology mobility, drones, technology adaptability, and remote power source availability there is no excuse to run culture based trials, except where unknown data is not available such as birth date, or other MED-Bio- historical demographic input is difficult and should be then questioned.
    In reading the article, most issues are related to trial recruitment, data collection, cultural demographic efforts. All true but we must not disregard, weight of results disparity based on sample collection, environmental extreme conditions, test conducted, chemistries, equipment used, instrument up-keep & historical review to qualification/validation and reporting methods. All are as much contributors as the meals injected prior to test, vitamin regime and any other cultural and biological, emotional impacting aspects.

    I actually love how David Thiel’s funded experimental trial was planned. Aside from FDA or SAFETY REVIEW BD. approval, that Herpes trial standardized a lot of inherent geographical, cultural, issues. By providing a hook “Caribbean trip” for otherwise probably afflicted vs. neglected population.
    Management would have wasted a lot of time and effort getting approval by either FDA or credentials worried Safety Board anyway. That was easy! Saved on already low standard (0.7%-1.9%) site inspections and providing trial and cohorts were run ethically and test were conducted accordingly, it looks like a promising model to me.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy